Editorial - (2011) Volume 2, Issue 2

BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers

Shouji Shimoyama*
Gastrointestinal Unit, Settlement Clinic, 4-20-7, Towa, Adachi-ku, Tokyo, 120-0003, Japan
*Corresponding Author: Shouji Shimoyama, M.D, Gastrointestinal Unit, Settlement Clinic, 4-20-7, Towa, Adachi-ku, Tokyo, 120-0003, Japan, Tel: +81-3- 3605-7747, Fax: +81-3-3605-0244 Email:

Abstract

The epidermal growth factor receptor (EGFR) has become an important therapeutic target in gastrointestinal cancers, especially in colorectal cancer. Stimulation of the EGFR activates at least five intracellular signal cascades such as RAS/RAF/MEK(mitogen-activated ERK activating kinase)/ERK(extracellular signal-regulated kinase), PI3K (phosphatidylinositol 3-kinase) /PTEN (phosphatase and tensin homolog)/AKT(v-akt murine thymoma viral oncogene homolog), STAT (signal transducer and activator of transcription), pospholipase C, and SRC/FAK(focal adhesion kinase). These either phosphorylate their target proteins in the cytoplasm or transmit signals from growth factor receptor to the nucleus, thereby initiating subsequent expression of genes that regulate cell proliferation, differentiation, angiogenesis, and survival [1] Recently, monoclonal antibodies have been developed to target EGFR and to inhibit subsequent cellular responses. They include anti-EGFR antibodies such as cetuximab (a chimeric monoclonal immunoglobulin G1 antibody), panitumumab (a fully human monoclonal immunoglobulin G2 antibody), and trastuzumab (a monoclonal antibody against human epidermal growth factor receptor-2 (HER2) as well as inhibitors of tyrosine kinase (TK) domain of EGFR or subsequent molecules such as gefitinib, erlotinib (both inhibitors of EGFR-TK), lapatinib (a dual inhibitor of HER2-TK and EGFR-TK), sunitinib (an inhibitor of the TK of various kinds of proteins), and sorafenib (an inhibitor of RAF, a downstream molecular of RAS). Among these, cetuximab, panitumumab, and trastuzumab have received the most intensive focus of research, and their efficacy has been clearly demonstrated -especially in gastric and colorectal cancer. However, it is also a fact that this efficacy is sometimes modest as objective response rates comprise at best 50% by adding trastuzumab to chemotherapy -even among HER-2 positive gastric cancer patients [2], or between 8 and 11% by cetuximab [3,4] or pamitumumab [5,6] monotherapy in colorectal cancer patients. The efficacy is thus presumed to be restricted to a certain segment of patients. Therefore, identification of predictive markers of response and resistance in performing the EGFR targeting therapies is urgently needed to stratify those patients benefiting most from them. This in turn obviate unnecessary or futile treatment and reduce health care costs, ultimately allowing treatment to be individualized.

The epidermal growth factor receptor (EGFR) has become an important therapeutic target in gastrointestinal cancers, especially in colorectal cancer. Stimulation of the EGFR activates at least five intracellular signal cascades such as RAS/RAF/MEK(mitogen-activated ERK activating kinase)/ERK(extracellular signal-regulated kinase), PI3K (phosphatidylinositol 3-kinase) /PTEN (phosphatase and tensin homolog)/AKT(v-akt murine thymoma viral oncogene homolog), STAT (signal transducer and activator of transcription), pospholipase C, and SRC/FAK(focal adhesion kinase). These either phosphorylate their target proteins in the cytoplasm or transmit signals from growth factor receptor to the nucleus, thereby initiating subsequent expression of genes that regulate cell proliferation, differentiation, angiogenesis, and survival [1]

Recently, monoclonal antibodies have been developed to target EGFR and to inhibit subsequent cellular responses. They include anti-EGFR antibodies such as cetuximab (a chimeric monoclonal immunoglobulin G1 antibody), panitumumab (a fully human monoclonal immunoglobulin G2 antibody), and trastuzumab (a monoclonal antibody against human epidermal growth factor receptor-2 (HER2) as well as inhibitors of tyrosine kinase (TK) domain of EGFR or subsequent molecules such as gefitinib, erlotinib (both inhibitors of EGFR-TK), lapatinib (a dual inhibitor of HER2-TK and EGFR-TK), sunitinib (an inhibitor of the TK of various kinds of proteins), and sorafenib (an inhibitor of RAF, a downstream molecular of RAS). Among these, cetuximab, panitumumab, and trastuzumab have received the most intensive focus of research, and their efficacy has been clearly demonstrated -especially in gastric and colorectal cancer. However, it is also a fact that this efficacy is sometimes modest as objective response rates comprise at best 50% by adding trastuzumab to chemotherapy -even among HER-2 positive gastric cancer patients [2], or between 8 and 11% by cetuximab [3,4] or pamitumumab [5,6] monotherapy in colorectal cancer patients. The efficacy is thus presumed to be restricted to a certain segment of patients. Therefore, identification of predictive markers of response and resistance in performing the EGFR targeting therapies is urgently needed to stratify those patients benefiting most from them. This in turn obviate unnecessary or futile treatment and reduce health care costs, ultimately allowing treatment to be individualized.

Components of the signal transduction cascade downstream to EGFR are sometimes mutated, which entails a continuous "switchon" state that triggers the aberrant activation of the cascades even in the absence of extracellular growth stimuli or in the presence of EGFR inhibition. For example, the benefit of cetuximab was limited to patients with wild type KRAS [7,8]. In addition, KRAS mutation predicted a lack of clinical benefit of panitumumab [6]. Accordingly, KRAS gene mutation is considered a predictor for the efficacy of anti- EGFR therapies, and testing for KRAS gene mutation status prior to the use of anti-EGFR antibodies is needed to distinguish between patients with the highest chance of benefiting from them and those for whom the administration would be presumably ineffective [7].

Despite the informative inverse association between KRAS mutation status and response to anti-EGFR therapies, only a subset of wild type KRAS carriers are responders to the anti-EGFR therapies, the objective response rates being 13-28% for cetuximab monotherapy [4,9], 44-61% for cetuximab in combination with chemotherapy [10-12], 17-29% for panitumumab monotherapy [6,13,14], and 35- 55% for panitumumab in combination with chemotherapy [15,16]. It is hypothesized that mutations in genes other than KRAS that are involved in the signal transduction cascade may account for the resistance to anti-EGFR therapies. In this regard, mutation analyses for RAF proteins, downstream proteins to KRAS in the MEK/ERK pathway, have been attractive targets for patient selection before considering anti-EGFR therapies because KRAS and BRAF mutation is usually mutually exclusive [17-19] - although double mutation of KRAS and BRAF does occur in some colorectal cancers [20]. The clinical relevance of BRAF mutation has been confirmed by several recent clinical studies demonstrating that anti-EGFR therapies resulted in a lack of response [17,21,22] and shorter survival [23-25] among patients harboring wild-type KRAS but mutant BRAF. The BRAF mutations could therefore provide useful information for predicting resistance to anti-EGFR therapies among patients bearing wild-type KRAS. How BRAF mutations work and contribute to initiate signal transduction cascades leading to resistance to anti-EGFR therapies has been most intensively investigated in malignant melanoma treatment. Extrapolation of the knowledge concerning malignant melanoma to gastrointestinal cancers could provide the next breakthrough in the field of molecular targeting therapies against gastrointestinal cancers.

The RAF gene family consists of ARAF, BRAF, and Raf-1 (formerly known as CRAF). All three proteins are serine/threonine kinases located in the RAS/RAF/MEK/ERK cascade as downstream effectors of RAS and are able to phosphorylate and activate MEK, which in turn activates ERK. These three RAF proteins exhibit different biochemical potencies, and BRAF is the most potent activator of MEK [26-28].

Table 1 lists the details of BRAF mutation reported in the COSMIC database (http://www.sanger.ac.uk/genetics/CGP/ cosmic/) [29]; the incidence of BRAF somatic mutations varies considerably among malignancies. The BRAF mutations occur at particularly high frequencies in malignant melanoma or in papillary thyroid cancer, with estimated incidences ranging from 30 to 70% [29,30] and from 40 to 70% (average, approximately 45%) [29-32], respectively. BRAF mutations are described at a moderate but significant frequency in colorectal (3-20%) [17,21-24,29,30], esophageal (2-11%) [29,33], biliary tract (10-20%) [29,30], and ovarian (5-10%) cancers [29,30]. They also occur at lower frequency in a wide variety of cancers such as in the stomach (0-3%) [29,33-36] and lung (2-3%) [29,33,37]. On the other hand, no BRAF mutations have been found so far in in situ breast cancer [29]. Interestingly, several reports suggest ethnic differences in BRAF mutation frequencies in colorectal cancer, these being 1.7-4.9% in China [38,39], 3.7% in Poland [40], and 0-2% in Iran [41,42], which contrast sharply with those in the Western hemisphere.

pharmacogenomics-pharmacoproteomics-BRAF-mutation

Table 1: BRAF mutation and detail of amino acid substitutions by tumor type listed in the COSMIC database [29].

In general, BRAF mutation occurs predominantly to convert valine at amino acid position 600 to other amino acids [43,44]. Such a panel of V600 mutations -a substitution of valine by other amino acid, e.g., V600E, V600K, V600D, V600R- comprise 80-90% of all BRAF mutations [43,44], and all are characterized as activating mutations [45]. Among them, a T1799A in exon 15 resulting in a substitution of glutamic acid (E) for valine (V) (V600E) (formerly referred to as the 599 position) [43,44] is the most common, accounting for up to 90% of all BRAF mutations [44]. It is able to elicit a 480-fold stronger phosphorylation activity in ERK than in wild type BRAF [45]. However, each malignancy exhibits different BRAF mutational spectra. V600E is common in malignant melanoma, thyroid cancer, and colorectal cancer, but it is comparatively rare in lung, prostate, and gastric cancers [29,37,44,46]. Mutations other than the V600 panel have been studied: some are hyperactive, but some display even decreased activity [45].

Neverthelss, it is worth noting that the hyperactive mutation (V600E) is the most predominant, and the absence of a V600E mutation is rather rare in human cancers. Such a high likelihood of "gain-offunction" mutation provides one explanation why BRAF mutation, even among wild-type KRAS carriers, is associated with resistance to anti-EGFR therapies and poor prognoses. The frequency and focality of this hyperactive mutation in certain cancers suggest its importance in cancer biology and potential as a therapy target.

Accordingly, several BRAF inhibitors have been developed and categorized as Pan-RAF inhibitors or BRAF specific inhibitors [47]. The efficacy of these inhibitors has been most extensively investigated in malignant melanoma. With regard to gastrointestinal cancers, several phase I/II studies are ongoing incorporating these inhibitors -alone or in combination with chemotherapeutic drugs- against colorectal, gastric, and esophageal cancers [48]. Despite some impressive clinical successes with the inhibitors [49,50], treatment responsive patients ultimately relapse as a result of acquired resistance [50], as is also observed in other tyrosine kinase inhibitors [51]. Several plausible mechanisms have been offered for this resistance, including CRAF bypass signaling, other BRAF mutations which initiate the MEK/ ERK axis, mutations of genes in downstream RAF that aberrantly upregulate the axis, and activation of altenative prosurvival pathways that may drive proliferation and resistance to apoptosis, all resulting in compensating for BRAF inhibition and bypassing the MEK/ERK pathway.

Very recent findings [52-54] have shed light on the complexities and signaling cross-talk associated with the inhibition of the BRAF mutant. BRAF inhibitions conduct a unique conformational change homodimer (CRAF/CRAF) or heterodimer (BRAF/CRAF). Under conditions of BRAF specific inhibitors and KRAS mutation, the inhibited BRAF molecule acts as a scaffold to transmit signals from mutant KRAS by the drug free CRAF present in the dimmer, suggesting that CRAF acts as a BRAF effector and a stimulator of the MEK/ERK cascade dependent on the KRAS mutation. Several findings support this hypothesis. The BRAF/CRAF heterodimer has vastly elevated kinase activity compared with the respective monomers or honodimers [55]. In addition, an increase in CRAF expression in response to BRAF inhibitor AZ628 is observed, and CRAF activation and heterodimelization with BRAF constitute critical components of the cellular response to the BRAF inhibitor, leading to resistance to the drug [56]. Moreover, the inhibition of BRAF might cooperate with oncogenic RAS to induce tumor growth [54]. Therefore, the inactivation of BRAF, under conditions of KRAS mutation, can ultimately lead to activation of the MEK/ERK pathway [56,57]. These mechanisms highlight the necessity to consider the KRAS mutation status before any administration of BRAF inhibitors. Although patients with KRAS mutation are resistant to cetuximab or panitumumab, BRAF inhibitors as alternative targeted therapies may be also ineffective or even hazardous in such patients: BRAF inhibitors can activate the MEK/ERK pathway in patients harboring KRAS mutation and thus are preferably avoided. Genotyping both KRAS and BRAF prior to administering BRAF inhibitors is hugely encouraged.

In this situation, pan-RAF inhibitors may be of value because they target all RAF isoforms and concurrently inhibit CRAF. As described above, the BRAF selective inhibitor results in pathway reactivation through CRAF, though this is less likely to occur with pan-RAF inhibitors even under the condition of KRAS mutation because CRAF is also inhibited. Accordingly, careful consideration is required when determining who is to be treated with a BRAF specific inhibitor; under certain conditions, the strategy of using pan-RAF inhibitors may actually be the better option.

Tumors harboring a unique dependency in the activated oncogene and activated pathway often develop clinical resistance against targeting therapies through point mutation or genetic amplification of the targeted locus. Elaboration of such resistance mechanisms has revealed the design of inhibitors with more enhanced potencies against a range of resistant variants. Continued attempts should be made to explore the complete atlas of genetic events responsible for sustained cell growth and the way such events functionally interact. The development of drugs selected for patients on the basis of the specific molecular features for which a response is needed will establish new means to attack cancer and ultimately to tailor treatment -instead of the traditional "one-drug-fits-all" approach.

References

Citation: Shimoyama S (2011) BRAF Mutations and their Implications in Molecular Targeting Therapies for Gastrointestinal Cancers. J Pharmacogenomics Pharmacoproteomics 2:e102.

Copyright: © 2011 Shimoyama S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.